We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

54 hedge funds and large institutions have $404M invested in ArriVent BioPharma in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 7 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 7

2% more funds holding

Funds holding: 53 → 54 (+1)

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

4% more capital invested

Capital invested by funds: $389M → $404M (+$15.3M)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

3.71% less ownership

Funds ownership: 68.37% → 64.66% (-3.7%)

Holders
54
Holders Change
+1
Holders Change %
+1.89%
% of All Funds
0.78%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
12
Increased
23
Reduced
7
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
HA
HHLR Advisors
Cayman Islands
+$9.91M
2
NHAS
Novo Holdings A/S
Denmark
+$7.54M
3
SCM
Suvretta Capital Management
New York
+$2.66M
4
HLAM
Hidden Lake Asset Management
New York
+$662K
5
State Street
State Street
Massachusetts
+$559K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$5.12M
2
Millennium Management
Millennium Management
New York
-$3.56M
3
FCM
Farallon Capital Management
California
-$2.71M
4
OCA
Octagon Capital Advisors
New York
-$2.51M
5
MA
MYDA Advisors
New York
-$536K
Name Holding Trade Value Shares
Change 		Change in
Stake
HA
1
HHLR Advisors
Cayman Islands
$83.2M +$9.91M +555,555 +14%
O
2
OrbiMed
New York
$56.2M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$36.2M +$2.62K +147 +0%
OCA
4
Octagon Capital Advisors
New York
$33.5M -$2.51M -140,532 -7%
SCM
5
Suvretta Capital Management
New York
$31.8M +$2.66M +148,994 +10%
SI
6
Sofinnova Investments
California
$31.5M – – –
NHAS
7
Novo Holdings A/S
Denmark
$27.8M +$7.54M +422,860 +39%
GCGM
8
General Catalyst Group Management
Massachusetts
$27.7M – – –
HH
9
HSG Holding
Hong Kong
$14.8M – – –
BlackRock
10
BlackRock
New York
$12.3M +$151K +8,461 +1%
Vanguard Group
11
Vanguard Group
Pennsylvania
$12.1M +$41.7K +2,339 +0.4%
CAM
12
Cormorant Asset Management
Massachusetts
$9.55M – – –
PA
13
Perceptive Advisors
New York
$7.7M – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$4.36M +$176K +9,895 +4%
State Street
15
State Street
Massachusetts
$2.85M +$559K +31,359 +26%
WP
16
Woodline Partners
California
$1.85M – – –
AA
17
AlphaCentric Advisors
Puerto Rico
$1.6M +$53.5K +3,000 +4%
Charles Schwab
18
Charles Schwab
California
$1.48M +$35.1K +1,967 +3%
Northern Trust
19
Northern Trust
Illinois
$1.45M -$3.9K -219 -0.3%
GCM
20
Ghisallo Capital Management
Massachusetts
$928K – – –
Morgan Stanley
21
Morgan Stanley
New York
$768K +$361K +20,243 +96%
HLAM
22
Hidden Lake Asset Management
New York
$689K +$662K +37,121 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$554K +$127K +7,140 +31%
AA
24
ALPS Advisors
Colorado
$485K +$466K +26,139 New
Walleye Capital
25
Walleye Capital
New York
$464K – – –
1
2 3

AVBP Hedge Fund Activity: Q2 2024 in Review

54 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q2 2024, worth a combined $404M — up 3.9% from $389M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new AVBP positions and 11 closed out — a net gain of 1 holder — while 23 added to existing stakes and 7 trimmed.

The largest buyer was HHLR Advisors, adding an estimated $9.91M. The largest seller was Citadel Advisors, exiting entirely with an estimated $5.12M sold.

  • 54 institutional investors held ArriVent BioPharma (AVBP) as of Q2 2024, up from 53 in Q1 2024.
  • Funds reported $404M of ArriVent BioPharma stock for Q2 2024, up 3.9% quarter-over-quarter.
  • 12 funds opened new ArriVent BioPharma positions in Q2 2024 and 11 closed out, a net change of +1 holder.
  • The largest ArriVent BioPharma buyer in Q2 2024 was HHLR Advisors, an estimated $9.91M added.
  • The largest ArriVent BioPharma seller in Q2 2024 was Citadel Advisors, an estimated $5.12M sold.

Based on aggregated 13F filings for Q2 2024.